

The only macrocyclic ionic molecule providing clinical confidence globally since 1989



## CLARISCAN™ (gadoterate meglumine) injection for intravenous use


(available from GE HealthCare since 2017)

Stability is one of the important considerations in molecule choice<sup>1</sup>

Macrocyclic, ionic molecule

Cagelike structure encloses the Gd<sup>3+</sup> ion<sup>1</sup>

Strong chemical bond<sup>2</sup>



Gadoterate meglumine



GE HealthCare

## Gadoterate meglumine, with the added commitment of GE HealthCare

Gd, gadolinium.

### IMPORTANT SAFETY INFORMATION ABOUT CLARISCAN™ (GADOTERATE MEGLUMINE)

#### WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

##### Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. CLARISCAN is not approved for intrathecal use.

##### Nephrogenic Systemic Fibrosis

GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of CLARISCAN in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

The risk for NSF appears highest among patients with:

- Chronic, severe kidney disease (GFR < 30 mL/min/1.73m<sup>2</sup>), or
- Acute kidney injury.

Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.


For patients at highest risk for NSF, do not exceed the recommended CLARISCAN dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

Please see Product Indications and Important Safety Information About Clariscan, including Boxed Warning, on the back page, and the Full Prescribing Information, [here](#).

## Providing an option for everyday practice<sup>3</sup>

### Clariscan is a gadolinium-based contrast agent indicated for

intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.



Clariscan is ALSO well-suited for use in at-risk patient populations, such as<sup>3</sup>:

- The elderly
- Pediatric patients from birth (term neonates  $\geq$  37 weeks gestational age)

During pregnancy, use only if imaging is essential and cannot be delayed

Recommended dose	0.2 mL/kg (0.1 mmol/kg) body weight	
Flow rate	Adults	Children
	~2 mL/second	1-2 mL/second

Please see dosing table in Section 2.1 of the full Prescribing Information for more detailed information.

CNS, central nervous system; IV, intravenous; MRI, magnetic resonance imaging.

Please see Product Indications and Important Safety Information About Clariscan, including Boxed Warning, on the back page, and the Full Prescribing Information, [here](#).

## Simple ordering process, and packaging with a 2D Data Matrix to transfer important information

### National Drug Codes (NDCs)/SKUs



Fill size	5mL in glass vial	10 mL in glass vial	15 mL in glass vial	20 mL in glass vial	10 mL in 20 mL prefilled syringe	15 mL in 20 mL prefilled syringe	20 mL in 20 mL prefilled syringe	100 mL +PLUSPAK polymer bottle
NDC	0407-2943-06	0407-2943-01	0407-2943-02	0407-2943-05	0407-2943-12	0407-2943-17	0407-2943-22	0407-2943-70
SKU	C105	C110	C115	C120	C210	C215	C220	C300

10

Each fill size can be ordered in packs of 10. Contact your GE HealthCare Account Manager or Customer Service at 800 292 8514 for more information.



With a 2D Data Matrix on each vial and outer box of 10 vials, information can be scanned rather than entered manually

Each 2D Data Matrix includes the following information:

- NDC
- Expiration date
- Lot number

Please see Product Indications and Important Safety Information About Clariscan, including Boxed Warning, on the back page, and the Full Prescribing Information, [here](#).

## IMPORTANT SAFETY INFORMATION ABOUT CLARISCAN™ (GADOTERATE MEGLUMINE)

### PRODUCT INDICATIONS AND USE:

CLARISCAN™ (gadoterate meglumine) is a prescription gadolinium-based contrast agent indicated for intravenous use with magnetic resonance imaging (MRI) in brain (intracranial), spine and associated tissues in adult and pediatric patients (including term neonates) to detect and visualize areas with disruption of the blood brain barrier (BBB) and/or abnormal vascularity.

### WARNING: RISK ASSOCIATED WITH INTRATHECAL USE and NEPHROGENIC SYSTEMIC FIBROSIS (NSF)

#### Risk Associated with Intrathecal Use

Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. CLARISCAN is not approved for intrathecal use.

#### Nephrogenic Systemic Fibrosis

GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of CLARISCAN in these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities. NSF may result in fatal or debilitating fibrosis affecting the skin, muscle and internal organs.

The risk for NSF appears highest among patients with:

- Chronic, severe kidney disease (GFR < 30 mL/min/1.73m<sup>2</sup>), or
- Acute kidney injury.

Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension, diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.

For patients at highest risk for NSF, do not exceed the recommended CLARISCAN dose and allow a sufficient period of time for elimination of the drug from the body prior to any re-administration.

### CONTRAINDICATIONS

History of clinically important hypersensitivity reactions to CLARISCAN.

### WARNINGS AND PRECAUTIONS

- **Risk Associated with Intrathecal Use:** Intrathecal administration of GBCAs can cause serious adverse reactions including death, coma, encephalopathy, and seizures. The safety and effectiveness of CLARISCAN have not been established with intrathecal use. CLARISCAN is not approved for intrathecal use.
- **Nephrogenic Systemic Fibrosis:** GBCAs increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of CLARISCAN among these patients unless the diagnostic information is essential and not available with non-contrast MRI or other modalities.
- **Hypersensitivity Reactions:** Anaphylactic and anaphylactoid reactions have been reported with CLARISCAN, involving cardiovascular, respiratory, and/or cutaneous manifestations. Some patients experienced circulatory collapse and died.

### References:

1. Tweedle MF et al. App Radiol. 2014;(suppl):1-11.
2. Morcos SK. Eur J Radiol. 2008;66:175-179.
3. Clariscan [prescribing information]. Malborough, MA: GE HealthCare; 2024.

- Before CLARISCAN administration, assess all patients for any history of a reaction to contrast media, bronchial asthma and/or allergic disorders. These patients may have an increased risk for a hypersensitivity reaction to CLARISCAN.
- **Gadolinium Retention:** Gadolinium is retained for months or years in several organs. The highest concentrations have been identified in the bone, followed by other organs (e.g. brain, skin, kidney, liver and spleen). While clinical consequences of gadolinium retention have not been established in patients with normal renal function, certain patients might be at higher risk. These include patients requiring multiple lifetime doses, pregnant and pediatric patients, and patients with inflammatory conditions. Minimize repetitive GBCA imaging studies, particularly closely spaced studies when possible.
- **Acute Kidney Injury:** In patients with chronically reduced renal function, acute kidney injury requiring dialysis has occurred with the use of GBCAs. The risk of acute kidney injury may increase with increasing dose of the contrast agent; administer the lowest dose necessary for adequate imaging.
- **Extravasation and Injection Site Reactions:** Ensure catheter and venous patency before the injection of CLARISCAN. Extravasation into tissues during CLARISCAN administration may result in tissue irritation.

### ADVERSE REACTIONS

- In clinical trials, the most frequent adverse reactions that occurred in > 0.2% of patients who received CLARISCAN included: nausea, headache, injection site pain, injection site coldness and rash.
- Serious adverse reactions in the Postmarketing experience have been reported with CLARISCAN. Serious adverse reactions include but are not limited to arrhythmia, cardiac arrest, respiratory arrest, pharyngeal edema, laryngospasm, bronchospasm, coma and convulsion.

### USE IN SPECIFIC POPULATIONS

- **Pregnancy:** GBCAs cross the human placenta and result in fetal exposure and gadolinium retention. Use only if imaging is essential during pregnancy and cannot be delayed.
- **Lactation:** There are no data on the presence of gadoterate in human milk, the effects on the breastfed infant, or the effects on milk production. However, published lactation data on other GBCAs indicate that 0.01 to 0.04% of the maternal gadolinium dose is present in breast milk.
- **Pediatric Use:** The safety of CLARISCAN has not been established in preterm neonates. No dosage adjustment according to age is necessary in pediatric patients.
- **Geriatric Use:** Use of CLARISCAN in elderly patients should be cautious, reflecting the greater frequency of impaired renal function and concomitant disease or other drug therapy. No age-related dosage adjustment is necessary.
- **Renal Impairment:** No CLARISCAN dosage adjustment is recommended for patients with renal impairment.

To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 1-800-654-0118 or by email at [gpv.drugsafety@gehealthcare.com](mailto:gpv.drugsafety@gehealthcare.com) or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch)

Please see [CLARISCAN full Prescribing Information](#), including the Medication Guide, for additional important safety information.

**Clariscan™**  
(gadoterate meglumine)  
injection for intravenous use

Products mentioned in the material may be subject to government regulations and may not be available in all countries. Shipment and effective sale can only occur after approval from the regulator. Please check with local GE HealthCare representative for details.

© 2024 GE HealthCare.

Clariscan is a trademark of GE HealthCare. GE is a trademark of General Electric Company used under trademark license.

July 2024  
JB08490US

